SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
bip22441-sup-0001-suppinfo.docx10598K

Fig S1. Competitive binding assay for control compound (see Table 1 for structure). FITC-labeled compound 5 was incubated with different concentrations of control compound with BT-474 cells. Cells were washed with PBS and fluorescence was detected using a plate reader. Ex λ 485 nm, Em λ 535 nm. There was no difference in fluorescence observed by FITC-5 at different concentrations of control suggesting that binding was not observed.

Fig. S2. Structure of compound 19.

Fig. S3. Structure of compound 20.

Fig. S4. PathHunter assay for control compound (CP from Tables 1 and 2) in HER2-HER3-transfected U2OS cells at different concentrations. Dose-response curve for CP suggests that there was no inhibition of PPI of HER2:HER3 by the compound (filled triangles) in the presence 0.3 µM heregulin a HER2:HER3 dimerization inducer. For comparison induction of dimerization by heregulin in a dose dependent manner is also shown (filled circles).

Fig. S5. Docking of compound 21 to HER2 domain IV. Possible modes of docking of compound 21 are shown. Two clusters were observed.

Table S1. Docking energy and binding site of docked compounds to HER2 domain IV.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.